Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $14.3000 (-0.69%) ($14.1600 - $14.6200) on Mon. Apr. 8, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.22% (three month average) | RSI | 61 | Latest Price | $14.3000(-0.69%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 1.2% a day on average for past five trading days. | Weekly Trend | FOLD advances 2.5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(61%) XBI(57%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.61% in a week (0% probabilities). VXX(-14%) TLT(-14%) UUP(-13%) VIXM(-8%) IFRA(-8%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.61% (StdDev 3.22%) | Hourly BBV | 0 () | Intraday Trend | -0.6% | | | |
|
5 Day Moving Average | $14.06(1.71%) | 10 Day Moving Average | $13.77(3.85%) | 20 Day Moving Average | $13.67(4.61%) | To recent high | -0.7% | To recent low | 30.4% | Market Cap | $3.693b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |